Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping versus continuing beta-blockers in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten
2026-526612-36-00Phase 4Authorised
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of mavacamten and carvedilol in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Ziekenhuis Oost-Limburg. Planned start Oct 2026; status: authorised.
02
Drugs
mavacamtencarvedilol
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2026-526612-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526612-36-00.